Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Getting to Know the Robot: Early Studies Assess Efficacy, Costs, and Outcomes With Robotic Prostatectomy

April 3rd 2013

Robot-assisted radical prostatectomy adoption into medical practice has been swift and encompassing, even as questions remain about its efficacy, added costs, and perioperative and longer-term outcomes versus alternatives.

Dr. Sandler on the Unique Characteristics of Radium-223

March 27th 2013

Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses radium-223, a novel alpha radiation emitting agent under evaluation by the FDA for patients with bone metastases from advanced castration-resistant prostate cancer (CRPC).

Dr. Gomella on Sequencing Prostate Cancer Therapies

March 25th 2013

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.

At 15 Years, Functional Declines Are Similar Regardless of Therapy Type for Prostate Cancer

March 22nd 2013

15 years after treatment, patients have roughly equal odds of experiencing declines in functions, with no significant difference associated with their choice of either radical prostatectomy or external-beam radiation therapy.

Dr. Petrylak on Sipuleucel-T Delaying First Opioid Use

March 21st 2013

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, discusses the relationship between sipuleucel-T and time to first use of an opioid analgesic in patients with metastatic castration-resistant prostate cancer.

Dr. Dreicer on Combination Therapies in Prostate Cancer

March 20th 2013

Robert Dreicer, MD, MS, from the Taussig Cancer Institute at the Cleveland Clinic, describes potential combination therapies currently being considered as treatments for men with prostate cancer.

Dr. Crawford Discusses Active Surveillance in Prostate Cancer

March 19th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses active surveillance as a treatment approach for men with prostate cancer.

Dr. Slovin on Prostate Cancer Immunotherapy Evolution

March 18th 2013

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, summarizes the development process of an effective immunotherapy for the treatment men with prostate cancer.

New Endocrine Therapies Expand Options for Advanced Prostate Cancer

March 18th 2013

Hormonal therapies that target androgen are the focus of several ongoing clinical trials for the treatment of advanced prostate cancer, and as more data accrues, clinicians are gaining valuable insight as to how these drugs can best be used to manage the disease.

Trials Should Test Combinations, Sequences of Novel Treatments for Prostate Cancer

March 18th 2013

Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.

Dr. Gomella on Surrogate Endpoints in Prostate Cancer

March 18th 2013

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital, describes the identification of appropriate surrogate endpoints for the evaluation of new therapies for patients with metastatic castration-resistant prostate cancer.

RARP Oncologic Outcomes Equivalent to Open Surgery for High-Risk Prostate Tumors

March 14th 2013

A novel retrospective study comparing robot-assisted radical prostatectomy and radical retropubic prostatectomy, in men with high-risk prostate cancer, found equivalent oncologic outcomes.

Dr. Cooperberg on Prostate Cancer Stage Migration

March 12th 2013

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the imminent stage migration that is likely to occur as new therapies become available expressly for metastatic prostate cancer.

Integrating Care for Prostate Patients: Multidisciplinary Model Pioneered

March 12th 2013

The multidisciplinary clinic for patients with prostate and other GU cancers at Thomas Jefferson University Hospital has served as a model for other departments interested in providing multidisciplinary care.

Dr. Hoffman on the Urologist's Influence on Treatment Choice

March 11th 2013

Karen E. Hoffman, MD, MHSc, MPH, from the MD Anderson Cancer Center, describes the diagnosing urologist's influence on the initial treatment selected for elderly men with favorable prostate cancer.

Dr. Antonarakis on Sequencing ADT and Sipuleucel-T

March 7th 2013

Emmanuel Stylianos Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a phase II trial evaluating the optimal sequence for sipuleucel-T and ADT in patients with biochemically recurrent prostate cancer.

Active Surveillance Safe Primary Management Strategy for Patients With Low-Grade Prostate Cancer

March 4th 2013

Treatment can safely be delayed in patients with low-grade prostate cancer who are carefully selected but then demonstrate disease progression after a period of active surveillance.

Dr. Vogelzang on Sequencing Abiraterone and Enzalutamide

March 1st 2013

Nicholas J. Vogelzang, MD, from Comprehensive Cancer Centers of Nevada, discusses sequencing abiraterone acetate and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer.

Dr. Gomella on the Value of a Multidisciplinary Cancer Center

February 27th 2013

Leonard G. Gomella, MD, discusses the benefits of the multidisciplinary center at Jefferson Kimmel Cancer Center.

Dr. William Oh Discusses Dasatinib in Metastatic CRPC

February 27th 2013

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses findings from the READY trial that added dasatinib to docetaxel as a treatment for men with metastatic castration-resistant prostate cancer.